Fig.Ā 3From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosisClinical outcomes for TCGA soft tissue sarcoma patients (nā=ā206). a KaplanāMeier curve of overall survival for CDKN2A altered versus non-CDKN2A altered patients (Cox Proportional Hazards adjusted for age, stage, and tumor size, pā=ā0.002). b KaplanāMeier curve of survival by sarcoma histologies shows no significant difference in survival overall (pā=ā0.392). c Histologic distribution of patients who are CDKN2A wild type c versus CDKN2A altered d shows increase in proportion of MPNST, MFS, and UPS with decrease in LMS and DDLPSBack to article page